About NeuroPace
NeuroPace is a company based in United States founded in 1997. NeuroPace has raised $263.56 million across 8 funding rounds from investors including Kleiner Perkins, Orbimed and Revelation Partners. The company has 184 employees as of December 31, 2024. NeuroPace offers products and services including RNS System. NeuroPace operates in a competitive market with competitors including Cadence Neuroscience, Engage Therapeutics, Cyberonics, CerboMed and NightWatch, among others.
- Headquarter United States
- Employees 184 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neuropace, Inc.
-
Annual Revenue
$79.91 M (USD)22.14as on Dec 31, 2024
-
Net Profit
-$27.14 M (USD)17.64as on Dec 31, 2024
-
EBITDA
-$19.9 M (USD)22.16as on Dec 31, 2024
-
Total Equity Funding
$263.56 M (USD)
in 8 rounds
-
Latest Funding Round
$69.39 M (USD), Series E
Aug 19, 2020
-
Investors
Kleiner Perkins
& 11 more
-
Employee Count
184
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NeuroPace
NeuroPace is a publicly listed company on the NASDAQ with ticker symbol NPCE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of NeuroPace
NeuroPace offers a comprehensive portfolio of products and services, including RNS System.
Delivers personalized therapy to reduce seizures in drug-resistant epilepsy patients.
People of NeuroPace
Unlock access to complete
Unlock access to complete
Leadership Team
11 people
Software Development Team
8 people
Sales and Marketing
3 people
Human Resources and Administration
3 people
Product Management Team
2 people
Legal and Compliance
2 people
Senior Team
2 people
Data Analysis and Operations Team
2 people
Unlock access to complete
Funding Insights of NeuroPace
NeuroPace has successfully raised a total of $263.56M across 8 strategic funding rounds. The most recent funding activity was a Series E round of $69.39 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series E — $69.4M
-
First Round
First Round
(09 Sep 2003)
- Investors Count 12
Investors in NeuroPace
NeuroPace has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Orbimed and Revelation Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NeuroPace
Financial Statements - NeuroPace
Neuropace Comparisons
Competitors of NeuroPace
NeuroPace operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cadence Neuroscience, Engage Therapeutics, Cyberonics, CerboMed and NightWatch, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Medical devices for treating neurological disorders like epilepsy are developed.
|
|
| domain | founded_year | HQ Location |
Inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures
|
|
| domain | founded_year | HQ Location |
Vagus nerve stimulation therapy is developed for epilepsy and depression.
|
|
| domain | founded_year | HQ Location |
Neuro-therapy solutions are developed for drug-resistant epilepsies and disorders.
|
|
| domain | founded_year | HQ Location |
Wearable armbands for detecting epileptic seizures during sleep are offered.
|
Frequently Asked Questions about NeuroPace
NeuroPace was founded in 1997 and raised its 1st funding round 6 years after it was founded.
NeuroPace is headquartered in United States.
NeuroPace is a funded company, having raised a total of $263.56M across 8 funding rounds to date. The company's 1st funding round was a Grant of $2.5M, raised on Sep 09, 2003.
As of Dec 31, 2024, the latest employee count at NeuroPace is 184.
Annual revenue of NeuroPace is $79.91M as on Dec 31, 2024.
Founded in 1997 in the United States, NeuroPace operates in the medical device sector, focusing on neurostimulation technologies. Implantable systems are designed to detect and respond to abnormal brain activity in adults with drug-resistant focal epilepsy, delivering targeted stimulation to reduce seizures. EEG data is collected and shared to support clinical monitoring and patient management. Resources, including support services, are provided to patients and healthcare professionals for ongoing care.
NeuroPace's top competitors include Engage Therapeutics, Cyberonics and Cadence Neuroscience.
NeuroPace offers RNS System.
Yes, NeuroPace is publicly traded on NASDAQ under the ticker symbol NPCE.
NeuroPace has 12 investors. Key investors include Kleiner Perkins, Orbimed, Revelation Partners, Accelmed, and Soleus Capital.
The ticker symbol of NeuroPace is NPCE on NASDAQ.